Table 3 Long-term prognosis of the LS and OS groups
Variable | LS group (n = 40) | OS group (n = 28) | p-value |
|---|---|---|---|
Postoperative follow-up, months | 9.37 (4.40–32.79) | 11.42 (7.25–22.45) | 0.478 |
Postoperative adjuvant therapy, n (%) | 18 (45.0) | 9 (32.14) | 0.323 |
Chemotherapy | 7 (17.5) | 8 (28.57) | 0.144 |
Chemotherapy + microwave ablation | 2 (5.0) | 0 | |
Chemotherapy + TACE | 2 (5.0) | 0 | |
Chemotherapy + targeted therapy | 1 (2.5) | 0 | |
Chemotherapy + immunotherapy | 4 (10.0) | 0 | |
Radiotherapy | 1 (2.5) | 0 | |
TACE | 0 | 1 (3.57) | |
Immunotherapy | 1 (2.5) | 0 | |
Total disease recurrence, n (%) | 14 (35.0) | 10 (35.71) | 0.783 |
Way of recurrence, n (%) | |||
Locoregional relapse | 9 (22.5) | 7 (25.0) | > 0.999 |
Distant metastases | 5 (12.5) | 3 (10.71) | |
Total death, n (%) | 22 (55.0) | 23 (82.14) | 0.036 |
Causes of death, n (%) | |||
Other | 13 (50.09) | 13 (56.52) | > 0.999 |
Cancer progression | 9 (40.91) | 10 (43.48) | |